Condition
Angiosarcoma of Skin
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06673628Phase 2RecruitingPrimary
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
NCT03544567Phase 2CompletedPrimary
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
NCT03921073Phase 2TerminatedPrimary
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
Showing all 3 trials